These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 16480430

  • 1. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants.
    Nachbaur D, Clausen J, Kircher B.
    Eur J Haematol; 2006 May; 76(5):414-9. PubMed ID: 16480430
    [Abstract] [Full Text] [Related]

  • 2. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation.
    Nachbaur D, Larcher C, Kircher B, Eibl G, Nussbaumer W, Gunsilius E, Haun M, Grünewald K, Gastl G.
    Ann Hematol; 2003 Oct; 82(10):621-7. PubMed ID: 12920570
    [Abstract] [Full Text] [Related]

  • 3. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N, Badsberg JH, Lönnqvist B, Ringdén O, Volin L, Rajantie J, Nikoskelainen J, Keiding N.
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [Abstract] [Full Text] [Related]

  • 4. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.
    Transpl Infect Dis; 2010 Aug 01; 12(4):322-9. PubMed ID: 20487414
    [Abstract] [Full Text] [Related]

  • 5. Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan.
    Tomonari A, Takahashi S, Ooi J, Tsukada N, Konuma T, Kato S, Kasahara S, Iseki T, Yamaguchi T, Tojo A, Asano S.
    Eur J Haematol; 2008 Mar 01; 80(3):251-7. PubMed ID: 18081702
    [Abstract] [Full Text] [Related]

  • 6. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning.
    Uzunel M, Remberger M, Sairafi D, Hassan Z, Mattsson J, Omazic B, Barkholt L, Ringdén O.
    Transplantation; 2006 Oct 15; 82(7):913-9. PubMed ID: 17038906
    [Abstract] [Full Text] [Related]

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 15; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 8. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E, Koza V, Vítek A, Mayer J, Sedlácek P, Zák P, Zapletalová J, Benesová K, Krejcová H, Steinerová K, Maresová I, Cetkovský P.
    Vnitr Lek; 2006 Dec 15; 52(12):1172-80. PubMed ID: 17299910
    [Abstract] [Full Text] [Related]

  • 9. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
    Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L, Zain J, Patane K, Kogut N, Nakamura R, Sarkodee-Adoo C, Forman SJ.
    Biol Blood Marrow Transplant; 2006 Dec 15; 12(12):1326-34. PubMed ID: 17162215
    [Abstract] [Full Text] [Related]

  • 10. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia.
    Schetelig J, Oswald O, Steuer N, Radonic A, Thulke S, Held TK, Oertel J, Nitsche A, Siegert W.
    Bone Marrow Transplant; 2003 Oct 15; 32(7):695-701. PubMed ID: 13130317
    [Abstract] [Full Text] [Related]

  • 11. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.
    Nakamura R, Battiwalla M, Solomon S, Follmann D, Chakrabarti S, Cortez K, Hensel N, Childs R, Barrett AJ.
    Biol Blood Marrow Transplant; 2004 Jan 15; 10(1):49-57. PubMed ID: 14752779
    [Abstract] [Full Text] [Related]

  • 12. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
    Bordon V, Bravo S, Van Renterghem L, de Moerloose B, Benoit Y, Laureys G, Dhooge C.
    Transpl Infect Dis; 2008 Feb 15; 10(1):19-23. PubMed ID: 17511814
    [Abstract] [Full Text] [Related]

  • 13. The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease.
    Kim SY, Lee DG, Kim MS, Kim HJ, Lee S, Min CK.
    Am J Hematol; 2008 Oct 15; 83(10):784-8. PubMed ID: 18661492
    [Abstract] [Full Text] [Related]

  • 14. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
    Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV.
    Liver Transpl; 2005 Jun 15; 11(6):700-4. PubMed ID: 15915496
    [Abstract] [Full Text] [Related]

  • 15. Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality.
    Matthes-Martin S, Lion T, Aberle SW, Fritsch G, Lawitschka A, Bittner B, Frommlet F, Gadner H, Peters C.
    Bone Marrow Transplant; 2003 May 15; 31(9):803-8. PubMed ID: 12732888
    [Abstract] [Full Text] [Related]

  • 16. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
    Trenschel R, Ross S, Hüsing J, Ottinger H, Elmaagacli A, Roggendorf M, Schaefer UW, Runde V.
    Bone Marrow Transplant; 2000 Mar 15; 25(6):665-72. PubMed ID: 10734302
    [Abstract] [Full Text] [Related]

  • 17. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies.
    Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV.
    Bone Marrow Transplant; 2007 Jul 15; 40(2):125-36. PubMed ID: 17530009
    [Abstract] [Full Text] [Related]

  • 18. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
    Winston DJ, Ho WG, Bartoni K, Champlin RE.
    Bone Marrow Transplant; 1993 Sep 15; 12(3):283-8. PubMed ID: 8241988
    [Abstract] [Full Text] [Related]

  • 19. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality.
    Bacigalupo A, Tedone E, Sanna MA, Moro F, Van Lint MT, Grazi G, Balestreri M, Frassoni F, Occhini D, Gualandi F.
    Haematologica; 1992 Sep 15; 77(6):507-13. PubMed ID: 1337746
    [Abstract] [Full Text] [Related]

  • 20. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.
    J Clin Oncol; 2008 Feb 01; 26(4):577-84. PubMed ID: 18086801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.